Tenet Healthcare (THC) stock surged 23% on Friday, putting it on pace for its biggest single-day gain since February. The move came after the company posted Q2 results that blew past Wall Street expectations and sharply lifted its full-year outlook.
Tenet Healthcare Corporation, THC
Tenet reported Q2 adjusted earnings of $6.12 per share, well ahead of the $4.26 analysts had forecast. Operating revenue rose 6.8% to $5.63 billion, topping the expected $5.43 billion.
The company also raised its full-year adjusted EPS guidance to a range of $20.30 to $21.69, up from the prior range of $16.38 to $18.68. Full-year net operating revenue guidance was lifted to $21.9 billion–$22.5 billion, versus the previous $21.5 billion–$22.3 billion.
$THC Q2 2026 earnings: Massive Margin Expansion and Buybacks Eclipse Volume Softness
Tenet Healthcare delivered a dramatic Q2 beat, fueled by exceptional hospital margin expansion and pricing power in its ambulatory segment. While net operating revenues grew a respectable 6.8%… pic.twitter.com/pxCFX3irFc
— Finsee (@Finsee_main) July 24, 2026
At the midpoint of each new range, both figures come in well ahead of what analysts had been expecting — $17.94 per share and $21.97 billion in revenue.
HCA Healthcare also reported Friday, but the reaction was far more muted. HCA rose 3.7%, compared to Tenet’s double-digit surge.
Much of that gap comes down to timing. HCA pre-announced its Q2 results on July 14, meaning Friday’s official report held few surprises for investors.
HCA posted Q2 adjusted EPS of $7.59, just above the $7.56 expected. Revenue climbed 9% to $20.23 billion, topping the $19.76 billion consensus.
However, a $400 million net benefit from Medicaid supplemental payments did a lot of the work. Excluding that, results were more complicated.
HCA noted a rise in uninsured patients, partly due to more people losing exchange-based coverage during the quarter. The company estimates that shift cost it roughly $400 million in pre-tax income.
HCA lowered its full-year EPS guidance to $28.70–$30.50, down from a prior range of $29.10–$31.50. The company also tightened its revenue outlook to $77 billion–$79.5 billion, compared with $76.5 billion–$80 billion previously.
The S&P 500 dipped slightly on Friday, making Tenet’s 23% gain stand out even more against the broader market backdrop.
Barclays responded by raising its price target on Tenet to $271 from $240, keeping an Overweight rating. The firm said Tenet’s Q2 performance “stands out and reinforces the case for a premium valuation,” particularly given guidance cuts from other hospital operators.
Tenet’s ambulatory surgery center network has been a key differentiator. While both companies run hospitals and outpatient facilities across the U.S., Tenet leans more heavily on its surgery center business, which has been a consistent driver of margin performance.
Barclays’ updated $271 price target represents further upside from Friday’s elevated levels following the post-earnings move.
The post Tenet Healthcare (THC) Stock Surges 23% After Massive Earnings Beat appeared first on CoinCentral.
